Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 9/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | MST1R | Q04912 | 2/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883270 | 0.86 | MET (0.49) | TP53THRBMETCSF1RPDGFRA | |
| SCHEMBL3882961 | 0.85 | TP53 (0.48) | TP53LMNARXFP1THRBMET | |
| SCHEMBL3885800 | 0.84 | MET (0.49) | TP53LMNARXFP1THRBMET | |
| SCHEMBL5313555 | 0.83 | MLKL (0.40) | TP53THRBMETMAPTAXL | |
| SCHEMBL3885761 | 0.81 | MET (0.60) | METAXLTYRO3LCKKIT | |
| SCHEMBL13759620 | 0.79 | MAPT (0.43) | TP53LMNARXFP1THRBMET | |
| SCHEMBL3883933 | 0.79 | MET (0.45) | TP53LMNARXFP1THRBMET | |
| SCHEMBL5317938 | 0.77 | TP53 (0.45) | TP53LMNARXFP1THRBMAPT | |
| SCHEMBL3886308 | 0.71 | MET (0.48) | TP53RXFP1THRBMETMAPT | |
| SCHEMBL1753925 | 0.69 | GAA (0.70) | TP53THRBALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742948-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | claimed |
| US-7566784-B2 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566784-B2 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | CDK2, ABL1, CDKN1A | TP53 394/4885LMNA 3679/4885RXFP1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.